Cargando…

Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study

BACKGROUND AND AIMS: The FORMA‐05 study compared the efficacy and safety of human fibrinogen concentrate (HFC) versus cryoprecipitate for hemostasis in bleeding patients undergoing cytoreductive surgery for pseudomyxoma peritonei (PMP). This subanalysis explores coagulation parameters in the FORMA‐0...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Ashok, Sargant, Nigel, Bell, John, Stanford, Sophia, Solomon, Cristina, Kruzhkova, Irina, Knaub, Sigurd, Mohamed, Faheez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521228/
https://www.ncbi.nlm.nih.gov/pubmed/37766781
http://dx.doi.org/10.1002/hsr2.1558
_version_ 1785110086768656384
author Roy, Ashok
Sargant, Nigel
Bell, John
Stanford, Sophia
Solomon, Cristina
Kruzhkova, Irina
Knaub, Sigurd
Mohamed, Faheez
author_facet Roy, Ashok
Sargant, Nigel
Bell, John
Stanford, Sophia
Solomon, Cristina
Kruzhkova, Irina
Knaub, Sigurd
Mohamed, Faheez
author_sort Roy, Ashok
collection PubMed
description BACKGROUND AND AIMS: The FORMA‐05 study compared the efficacy and safety of human fibrinogen concentrate (HFC) versus cryoprecipitate for hemostasis in bleeding patients undergoing cytoreductive surgery for pseudomyxoma peritonei (PMP). This subanalysis explores coagulation parameters in the FORMA‐05 patients, with a focus on the seven patients who developed thromboembolic events (TEEs). METHODS: FORMA‐05 was a prospective, randomized, controlled phase 2 study in which patients with predicted blood loss ≥2 L received HFC (4 g) or cryoprecipitate (two pools of five units), repeated as needed. Plasma fibrinogen, platelet count, factor (F) XIII, FVIII, von Willebrand Factor (VWF) antigen and ristocetin cofactor activity levels, EXTEM A20, FIBTEM A20, and endogenous thrombin potential (ETP) were measured perioperatively. RESULTS: Fibrinogen, platelet count, EXTEM and FIBTEM A20, FXIII, FVIII, VWF levels, and ETP were maintained throughout surgery in both the HFC group (N = 21) and the cryoprecipitate group (N = 23). Seven TEEs were observed in the cryoprecipitate group. The two patients developing deep vein thromboses (DVT) appeared to have a procoagulant status preoperatively, with distinctively higher fibrinogen level, FIBTEM A20, and platelet levels, all of which persisted perioperatively. The five patients developing pulmonary embolism (PE) had slightly higher VWF levels preoperatively, with a disproportionate increase intraoperatively (postcryoprecipitate administration) and postoperatively. CONCLUSIONS: Patients treated with HFC versus cryoprecipitate showed broad overlaps in coagulation parameters. Patients with PE experienced a disproportionate VWF rise following cryoprecipitate administration, whereas patients developing DVT displayed a procoagulant status before and following surgery. Preoperative testing may allow these patients to be identified.
format Online
Article
Text
id pubmed-10521228
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105212282023-09-27 Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study Roy, Ashok Sargant, Nigel Bell, John Stanford, Sophia Solomon, Cristina Kruzhkova, Irina Knaub, Sigurd Mohamed, Faheez Health Sci Rep Original Research BACKGROUND AND AIMS: The FORMA‐05 study compared the efficacy and safety of human fibrinogen concentrate (HFC) versus cryoprecipitate for hemostasis in bleeding patients undergoing cytoreductive surgery for pseudomyxoma peritonei (PMP). This subanalysis explores coagulation parameters in the FORMA‐05 patients, with a focus on the seven patients who developed thromboembolic events (TEEs). METHODS: FORMA‐05 was a prospective, randomized, controlled phase 2 study in which patients with predicted blood loss ≥2 L received HFC (4 g) or cryoprecipitate (two pools of five units), repeated as needed. Plasma fibrinogen, platelet count, factor (F) XIII, FVIII, von Willebrand Factor (VWF) antigen and ristocetin cofactor activity levels, EXTEM A20, FIBTEM A20, and endogenous thrombin potential (ETP) were measured perioperatively. RESULTS: Fibrinogen, platelet count, EXTEM and FIBTEM A20, FXIII, FVIII, VWF levels, and ETP were maintained throughout surgery in both the HFC group (N = 21) and the cryoprecipitate group (N = 23). Seven TEEs were observed in the cryoprecipitate group. The two patients developing deep vein thromboses (DVT) appeared to have a procoagulant status preoperatively, with distinctively higher fibrinogen level, FIBTEM A20, and platelet levels, all of which persisted perioperatively. The five patients developing pulmonary embolism (PE) had slightly higher VWF levels preoperatively, with a disproportionate increase intraoperatively (postcryoprecipitate administration) and postoperatively. CONCLUSIONS: Patients treated with HFC versus cryoprecipitate showed broad overlaps in coagulation parameters. Patients with PE experienced a disproportionate VWF rise following cryoprecipitate administration, whereas patients developing DVT displayed a procoagulant status before and following surgery. Preoperative testing may allow these patients to be identified. John Wiley and Sons Inc. 2023-09-26 /pmc/articles/PMC10521228/ /pubmed/37766781 http://dx.doi.org/10.1002/hsr2.1558 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Roy, Ashok
Sargant, Nigel
Bell, John
Stanford, Sophia
Solomon, Cristina
Kruzhkova, Irina
Knaub, Sigurd
Mohamed, Faheez
Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study
title Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study
title_full Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study
title_fullStr Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study
title_full_unstemmed Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study
title_short Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study
title_sort comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: subanalysis from a randomized, controlled phase 2 study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521228/
https://www.ncbi.nlm.nih.gov/pubmed/37766781
http://dx.doi.org/10.1002/hsr2.1558
work_keys_str_mv AT royashok comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study
AT sargantnigel comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study
AT belljohn comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study
AT stanfordsophia comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study
AT solomoncristina comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study
AT kruzhkovairina comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study
AT knaubsigurd comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study
AT mohamedfaheez comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study